http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Development of CAD for Zone Dividing of Process Control Networks to Improve Cyber Security
Hiroki Moritani,Shuichi Yogo,Takahito Morita,Midori Kojima,Kento Watanabe,Jing Sun,Ichiro Koshijima,Yoshihiro Hashimoto 제어로봇시스템학회 2014 제어로봇시스템학회 국제학술대회 논문집 Vol.2014 No.10
Recently, cyber security becomes a serious problem for not only OA (Office Automation) systems but also PA (Process Automation) and FA (Factory Automation) systems. Even the controllers, which are not connected to Internet directly, have been attacked with malwares, such as Stuxnet and Quantum. When control system fails, it may lead to serious accidents such as explosion or leakage of poisonous and deleterious substances. For process control, cyber-attack is one of the causes to threaten safety. The authors of this paper had proposed zone division of process control networks to ensure cyber security and safety. To apply the method, it is necessary to build CE (Cause Effect) matrices which express the qualitative information of the plant and controllers. It is very troublesome for large-scale plants. CAD (Computer Aided Design) tool for zone dividing is proposed in this paper. CE matrices are generated by using DAE (Differential and Algebraic Equation) registered in equipment modules of plant CAD such as ASPEN or Pro II. The candidates of zone division of process control networks, which can assure the safety against concealment and remote operation by cyber attackers, can be proposed.
Hiroki Mieno,Kazuhito Yoneda,Nobuhiro Terao,Kengo Yoshii,Kentaro Kojima,Kenji Nagata,Chie Sotozono 대한안과학회 2020 Korean Journal of Ophthalmology Vol.34 No.4
Purpose: To investigate the efficacy of aflibercept for the treatment of diabetic macular edema via a treat-and-extend regimen. Methods: This prospective, single-center, open-label, interventional study involved 30 patients with a best-corrected visualacuity (BCVA) ≤0.6 and a central retinal thickness (CRT) ≥300 μm. The enrolled eyes each received a monthly intravitreal afliberceptinjection until the CRT decreased below 300 μm, upon which the administration interval was extended for 1 monthuntil the CRT once again increased to ≥300 μm. Main outcome measures were median BCVA and CRT at 6 and 12 monthsafter initiation of treatment via last observation carried forward analysis, the median number of injections over the 12months, and the effects on the diabetic retinopathy severity scale (DRSS) score of the patients who completed the 12-monthfollow-up period. Results: Of the 30 enrolled patients, 29 and 25 respectively completed the 6- and 12-month follow-up examinations. Frombaseline to 6 and 12 months after treatment initiation, the median BCVA (logarithm of the minimum angle of resolution) significantlyimproved from 0.52 to 0.30 and 0.35, respectively, and the median CRT significantly decreased from 439.5 to 268.5and 249.0 μm, respectively. The median number of injections over the 12-month follow-up period was 6.0. Compared tobaseline, the DRSS score at 12 months was improved by 2 steps in 16% of patients; in no cases did the DRSS score worsen orimprove by three steps or more. Conclusions: When administered in a treat-and-extend regimen, aflibercept is an effective treatment option for diabeticmacular edema.